{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37","upperLimit":"68","value":"54"}]}],"title":"Overall survival"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16","upperLimit":"48","value":"31"}]}],"title":"Progression free survival"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Kaplan-Meier estimates for overall survival (OS) and progression free survival (PFS) assessed at two years.","dispersionType":"95% Confidence Interval","groups":[{"description":"See Detailed Description\n\nrituximab: Given IV\n\ncyclosporine: Given orally\n\nfludarabine phosphate: Given IV\n\nmycophenolate mofetil: Given orally\n\nyttrium Y 90 ibritumomab tiuxetan: Given IV\n\nperipheral blood stem cell transplantation: Undergo transplantation\n\nallogeneic hematopoietic stem cell transplantation: Undergo transplantation\n\ntotal-body irradiation: Undergo TBI","id":"OG000","title":"Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 8 years","title":"Overall and Progression-free Survival","type":"SECONDARY","unitOfMeasure":"percent"}